Symbols / CNSP $2.28 -6.94%
CNSP Chart
About
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.31M |
| Enterprise Value | -8.31M | Income | -13.07M | Sales | — |
| Book/sh | 17.25 | Cash/sh | 15.90 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | 0.00 | Forward P/E | -5.85 | PEG | — |
| P/S | — | P/B | 0.13 | P/C | — |
| EV/EBITDA | 0.63 | EV/Sales | — | Quick Ratio | 5.04 |
| Current Ratio | 5.82 | Debt/Eq | 0.31 | LT Debt/Eq | — |
| EPS (ttm) | 776.03 | EPS next Y | -0.39 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 17:00 | ROA | -85.59% |
| ROE | -197.11% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 574.58K |
| Shs Float | 523.81K | Short Float | 7.00% | Short Ratio | 2.00 |
| Short Interest | — | 52W High | 55.20 | 52W Low | 2.25 |
| Beta | 0.46 | Avg Volume | 43.97K | Volume | 22.14K |
| Target Price | $10.00 | Recom | Buy | Prev Close | $2.45 |
| Price | $2.28 | Change | -6.94% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.00
Mean price target
2. Current target
$2.41
Latest analyst target
3. DCF / Fair value
$-370.73
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.41
Low
$10.00
High
$10.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-12 | up | Maxim Group | Hold → Buy | $20 |
| 2025-03-25 | down | Maxim Group | Buy → Hold | — |
- CNS Pharma shifts from single cancer focus to hunting new brain and tumor drugs - Stock Titan Wed, 11 Mar 2026 12
- CNS Pharmaceuticals Unveils Strategic Pivot to Broader Oncology - The Globe and Mail hu, 12 Mar 2026 13
- New CNS Pharmaceuticals (NASDAQ: CNSP) team drives strategic pivot - Stock Titan Wed, 11 Mar 2026 12
- symbol__ Stock Quote Price and Forecast - CNN Fri, 16 Feb 2024 17
- CNS Pharmaceuticals (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology and Oncology Pipeline Expansion - The Globe and Mail Wed, 11 Mar 2026 16
- CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Yahoo Finance ue, 13 May 2025 07
- Brain cancer drug developer hires veteran surgeon to lead studies - Stock Titan Mon, 02 Mar 2026 08
- CNS Pharmaceuticals Appoints New Chief Medical Officer - TipRanks Mon, 02 Mar 2026 08
- CNS Pharmaceuticals Restructures Finance Leadership, Appoints New CFO - The Globe and Mail Wed, 18 Feb 2026 08
- 9,500 RSUs awarded to CNS Pharmaceuticals (CNSP) CFO - Stock Titan Wed, 04 Mar 2026 08
- CNS Pharmaceuticals (CNSP) Receives a Buy from Maxim Group - The Globe and Mail Sat, 07 Mar 2026 08
- Brain cancer drug developer hires CFO, CTO and CBO in strategic reset - Stock Titan ue, 17 Feb 2026 08
- CNS Pharmaceuticals (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer - The Globe and Mail Mon, 02 Mar 2026 08
- CNS Pharmaceuticals (CNSP) files insider Form 3 for Chief Financial Officer - Stock Titan Wed, 04 Mar 2026 08
- New CNS Pharmaceuticals CEO launches broad review built around lead cancer drug - Stock Titan ue, 27 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -14.84M | -18.83M | -15.26M | -14.47M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -14.86M | -18.85M | -15.27M | -14.50M |
| ReconciledDepreciation | 3.31K | 4.13K | 11.76K | 13.07K |
| EBITDA | -14.84M | -18.83M | -15.26M | -14.47M |
| EBIT | -14.84M | -18.84M | -15.27M | -14.49M |
| NetInterestIncome | 44.14K | 13.88K | -7.03K | -9.29K |
| InterestExpense | 16.12K | 13.80K | 7.03K | 9.29K |
| InterestIncome | 60.26K | 27.69K | 0.00 | |
| NormalizedIncome | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -14.86M | -18.85M | -15.27M | -14.50M |
| TotalExpenses | 14.90M | 18.87M | 15.27M | 14.49M |
| TotalOperatingIncomeAsReported | -14.90M | -18.87M | -15.27M | -14.49M |
| DilutedAverageShares | 117.80K | 207.00 | 53.00 | 31.00 |
| BasicAverageShares | 117.80K | 207.00 | 53.00 | 31.00 |
| DilutedEPS | -126.13 | -91.07K | -288.19K | -467.59K |
| BasicEPS | -126.13 | -91.07K | -288.19K | -467.59K |
| DilutedNIAvailtoComStockholders | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncomeCommonStockholders | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncome | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncomeIncludingNoncontrollingInterests | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncomeContinuousOperations | -14.86M | -18.85M | -15.27M | -14.50M |
| PretaxIncome | -14.86M | -18.85M | -15.27M | -14.50M |
| NetNonOperatingInterestIncomeExpense | 44.14K | 13.88K | -7.03K | -9.29K |
| InterestExpenseNonOperating | 16.12K | 13.80K | 7.03K | 9.29K |
| InterestIncomeNonOperating | 60.26K | 27.69K | 0.00 | |
| OperatingIncome | -14.90M | -18.87M | -15.27M | -14.49M |
| OperatingExpense | 14.90M | 18.87M | 15.27M | 14.49M |
| ResearchAndDevelopment | 9.29M | 14.10M | 9.30M | 9.81M |
| SellingGeneralAndAdministration | 5.61M | 4.77M | 5.97M | 4.68M |
| GeneralAndAdministrativeExpense | 5.61M | 4.77M | 5.97M | 4.68M |
| OtherGandA | 5.61M | 4.77M | 5.97M | 4.68M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 117.80K | 207.00 | 53.00 | 31.00 |
| ShareIssued | 117.80K | 207.00 | 53.00 | 31.00 |
| TotalDebt | 326.07K | 300.81K | 409.97K | 387.79K |
| TangibleBookValue | 6.18M | -4.43M | 8.13M | 6.16M |
| InvestedCapital | 6.50M | -4.13M | 8.54M | 6.55M |
| WorkingCapital | 6.13M | -4.54M | 7.64M | 4.88M |
| NetTangibleAssets | 6.18M | -4.43M | 8.13M | 6.16M |
| CommonStockEquity | 6.18M | -4.43M | 8.13M | 6.16M |
| TotalCapitalization | 6.18M | -4.43M | 8.13M | 6.16M |
| TotalEquityGrossMinorityInterest | 6.18M | -4.43M | 8.13M | 6.16M |
| StockholdersEquity | 6.18M | -4.43M | 8.13M | 6.16M |
| RetainedEarnings | -84.42M | -69.57M | -50.72M | -35.44M |
| AdditionalPaidInCapital | 90.60M | 65.13M | 58.85M | 41.60M |
| CapitalStock | 1.41K | 2.00 | 1.62K | 949.00 |
| CommonStock | 1.41K | 2.00 | 1.62K | 949.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.52M | 6.13M | 4.92M | 2.59M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 2.52M | 6.13M | 4.92M | 2.59M |
| CurrentDebtAndCapitalLeaseObligation | 326.07K | 300.81K | 409.97K | 387.79K |
| CurrentDebt | 326.07K | 300.81K | 409.97K | 387.79K |
| CurrentNotesPayable | 326.07K | 300.81K | 409.97K | 387.79K |
| PayablesAndAccruedExpenses | 2.20M | 5.83M | 4.51M | 2.21M |
| CurrentAccruedExpenses | 828.39K | 224.95K | ||
| Payables | 3.68M | 1.98M | ||
| AccountsPayable | 3.68M | 1.98M | ||
| TotalAssets | 8.70M | 1.70M | 13.05M | 8.76M |
| TotalNonCurrentAssets | 42.44K | 109.68K | 488.47K | 1.28M |
| NonCurrentPrepaidAssets | 36.43K | 104.75K | 482.81K | 929.69K |
| NonCurrentDeferredAssets | 0.00 | 334.14K | ||
| NetPPE | 6.00K | 4.93K | 5.66K | 16.11K |
| CurrentAssets | 8.66M | 1.59M | 12.56M | 7.48M |
| OtherCurrentAssets | 1.29M | 839.59K | 2.51M | 2.47M |
| CurrentDeferredAssets | 20.64K | 202.86K | 0.00 | |
| PrepaidAssets | 2.51M | 2.47M | ||
| Receivables | 882.54K | 0.00 | ||
| AccountsReceivable | 882.54K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 6.46M | 548.72K | 10.06M | 5.00M |
| CashAndCashEquivalents | 6.46M | 548.72K | 10.06M | 5.00M |
| CashFinancial | 548.72K | 10.06M | 5.00M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -17.12M | -14.14M | -10.56M | -13.54M |
| RepaymentOfDebt | -300.81K | -438.73K | -427.70K | -477.49K |
| IssuanceOfCapitalStock | 23.38M | 2.32M | 16.04M | 4.65M |
| CapitalExpenditure | -4.19K | -3.90K | -4.42K | -5.75K |
| InterestPaidSupplementalData | 13.60K | 13.80K | 8.09K | 9.77K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 6.46M | 548.72K | 10.06M | 5.00M |
| BeginningCashPosition | 548.72K | 10.06M | 5.00M | 14.04M |
| ChangesInCash | 5.91M | -9.51M | 5.05M | -9.03M |
| FinancingCashFlow | 23.03M | 4.64M | 15.61M | 4.51M |
| CashFlowFromContinuingFinancingActivities | 23.03M | 4.64M | 15.61M | 4.51M |
| NetOtherFinancingCharges | -66.75K | -202.86K | ||
| ProceedsFromStockOptionExercised | 21.32K | 2.96M | 2.73K | 332.75K |
| NetCommonStockIssuance | 23.38M | 2.32M | 16.04M | 4.65M |
| CommonStockIssuance | 23.38M | 2.32M | 16.04M | 4.65M |
| NetIssuancePaymentsOfDebt | -300.81K | -438.73K | -427.70K | -477.49K |
| NetShortTermDebtIssuance | -300.81K | -438.73K | -427.70K | -477.49K |
| ShortTermDebtPayments | -300.81K | -438.73K | -427.70K | -477.49K |
| NetLongTermDebtIssuance | -477.49K | |||
| LongTermDebtPayments | -477.49K | |||
| InvestingCashFlow | -4.19K | -3.90K | -4.42K | -5.75K |
| CashFlowFromContinuingInvestingActivities | -4.19K | -3.90K | -4.42K | -5.75K |
| NetPPEPurchaseAndSale | -4.19K | -3.90K | -4.42K | -5.75K |
| PurchaseOfPPE | -4.19K | -3.90K | -4.42K | -5.75K |
| OperatingCashFlow | -17.11M | -14.14M | -10.56M | -13.54M |
| CashFlowFromContinuingOperatingActivities | -17.11M | -14.14M | -10.56M | -13.54M |
| ChangeInWorkingCapital | -3.69M | 3.70M | 3.16M | -780.02K |
| ChangeInPayablesAndAccruedExpense | -3.63M | 1.32M | 2.30M | 740.26K |
| ChangeInAccruedExpense | 603.44K | -294.86K | ||
| ChangeInPayable | 1.70M | 1.04M | ||
| ChangeInAccountPayable | 1.70M | 1.04M | ||
| ChangeInPrepaidAssets | -59.97K | 2.38M | 860.45K | -1.52M |
| OtherNonCashItems | 596.30K | |||
| StockBasedCompensation | 838.96K | 1.01M | 1.20M | 1.72M |
| AssetImpairmentCharge | 0.00 | 334.14K | 0.00 | |
| DepreciationAmortizationDepletion | 3.31K | 4.13K | 11.76K | 13.07K |
| DepreciationAndAmortization | 3.31K | 4.13K | 11.76K | 13.07K |
| Depreciation | 3.31K | 4.13K | 11.76K | 13.07K |
| OperatingGainsLosses | -190.00 | 498.00 | 3.11K | |
| GainLossOnSaleOfPPE | -190.00 | 498.00 | 3.11K | 0.00 |
| NetIncomeFromContinuingOperations | -14.86M | -18.85M | -15.27M | -14.50M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CNSP
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|